Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.
Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia / R. Ricotta, G. Cerea, I. Schiavetto, M.R. Maugeri, P. Pedrazzoli, S. Siena. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 2:6(2006), pp. 667-676.
|Titolo:||Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia|
|Parole Chiave:||colony-stimulating factor; granulocyte colony-stimulating factor; hematopoietic growth factor; neutropenia; pegfilgrastim|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2006|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2217/147966126.96.36.1997|
|Appare nelle tipologie:||01 - Articolo su periodico|